Age Comparisons of Endometrial Cancer Clinicopathology and Treatment in the United States Military Health System
- 12 February 2026
- journal article
- Published by Oxford University Press (OUP) in Military Medicine
- Vol. 191 (9-10) , e2074-e2084
Abstract
Introduction: Endometrial cancer incidence is rising in the United States, including among women younger than 50 years, raising concern for women serving on active duty, retirees, and their dependents. Age-related differences in clinicopathologic features and treatment have been documented in the general U.S. population and the differences may be influenced by access to care. We aimed to study clinicopathologic and treatment features of women within the Department of War (DoW) Military Health System (MHS) to better understand age-related differences in tumor characteristics, surgical management, and adjuvant therapy by age in this universal access setting. Materials and Methods: We conducted a retrospective cohort study using the Military Cancer Epidemiology (MilCanEpi) database, which links the DoW cancer registry and medical claims data. Women diagnosed with endometrial cancer from 2001 to 2014 who underwent hysterectomy within 6 months of diagnosis were included. Modified Poisson regression was used to estimate adjusted risk ratios (ARRs) for advanced tumor stage (II-IV vs. I), aggressive histological subtypes (high-grade endometrioid endometrial carcinoma [EEC] or non-EEC vs. low-grade EEC), surgical approach, and adjuvant therapy (chemotherapy or radiation) by age group: 18-49, 50-64, and ≥65 years. Results: Among 1,223 patients, 16% were aged 18-49, 61% aged 50-64, and 23% aged ≥65. Compared with women aged 50-64, those aged 18-49 were less likely to have aggressive histologic subtypes (ARR = 0.65; 95% CI = 0.44-0.96), while those aged ≥65 were at higher risk for more aggressive histologic subtypes (ARR = 1.54; 95% CI = 1.25-1.90). No significant age-related differences were observed in tumor stage, time to surgery, surgical approach, or lymphadenectomy. Among patients with aggressive histologic subtypes (n = 287), receipt of adjuvant therapy did not differ significantly by age (18-49 years: ARR = 0.84, 95% CI = 0.58-1.21; ≥65 years: ARR = 0.92, 95% CI = 0.78-1.08) relative to women aged 50-64 years at diagnosis. Conclusions: Within the MHS, age-related differences in endometrial cancer were confined to tumor histology, with younger women less likely and older women more likely to present with aggressive subtypes. This is consistent with that reported in the general U.S. population. Importantly, no age-related differences were observed in surgical management or receipt of adjuvant therapy when adjusted for tumor features. This may suggest the role of healthcare access in mitigating age-related treatment gaps observed in the general population.Keywords
Funding Information
- Murtha Cancer Center Research Program of the Department of Surgery
- Uniformed Services University of the Health Sciences
- Henry M. Jackson Foundation (USUHS HHU000116-2-0014)
- Henry M. Jackson Foundation (HU0001-18-2-0032)
This publication has 50 references indexed in Scilit:
- Racial and ethnic differences in tumor characteristics among endometrial cancer patients in an equal-access healthcare populationCancer Causes & Control, 2023
- Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine CancerJAMA Network Open, 2023
- Association Between Primary Care Use Prior to Cancer Diagnosis and Subsequent Cancer Mortality in the Veterans Affairs Health SystemJAMA Network Open, 2022
- US Health Care Spending by Payer and Health Condition, 1996-2016JAMA, 2020
- Adjuvant chemotherapy in endometrial cancerCancer Chemotherapy and Pharmacology, 2020
- Management of endometrial cancer in patients aged 80 years and olderEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2019
- Use and outcomes of minimally invasive hysterectomy for women with nonendometrioid endometrial cancersAmerican Journal of Obstetrics and Gynecology, 2018
- Adapting the Elixhauser comorbidity index for cancer patientsCancer, 2018
- Survival implications of time to surgical treatment of endometrial cancersAmerican Journal of Obstetrics and Gynecology, 2017
- Endometrial cancer in women 45 years of age or younger: A clinicopathological analysisAmerican Journal of Obstetrics and Gynecology, 2005